GI Pathophysiology Course

Physiologic Basis of Current and Future Approaches to Non-Alcoholic Fatty Liver Disease

Speaker(s)

• 

  Zobair Younossi, MD, MPH, FACG

  Chairman, Department of Medicine, Inova Fairfax Medical Campus; Professor of Medicine, Virginia Commonwealth University, Inova Campus; Affiliate Professor of Biomedical Sciences, George Mason University
  Inova Health System
  Washington, DC, US

  Consultant: AbbVie, BMS, Gilead, Intercept, Merck, Novartis, Novo Nordisk, Shionogi, Terns, Viking
  

Learning Objectives:

• Develop a conceptual framework for the appropriate utilization of novel therapeutics for fatty liver diseases.